698 Shares in Johnson & Johnson $JNJ Acquired by Livelsberger Financial Advisory

Livelsberger Financial Advisory purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 698 shares of the company’s stock, valued at approximately $107,000. Johnson & Johnson comprises 2.1% of Livelsberger Financial Advisory’s investment portfolio, making the stock its 17th largest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC grew its stake in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after buying an additional 1,022 shares during the period. Shell Asset Management Co. grew its stake in Johnson & Johnson by 6.2% during the fourth quarter. Shell Asset Management Co. now owns 10,725 shares of the company’s stock worth $1,551,000 after buying an additional 630 shares during the period. Tang Capital Management LLC grew its stake in Johnson & Johnson by 58.7% during the fourth quarter. Tang Capital Management LLC now owns 7,959 shares of the company’s stock worth $1,151,000 after buying an additional 2,944 shares during the period. Finally, Strive Asset Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $650,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $178.10 on Monday. The company has a market capitalization of $428.93 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The firm has a fifty day simple moving average of $170.81 and a 200-day simple moving average of $161.27. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the firm posted $2.82 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on JNJ shares. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Finally, Guggenheim restated a “neutral” rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.